Top Markets
Coin of the day
ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc.

ZVSA
Rang in Aktien #38791
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical... ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Aktienkurs
$0.099
Marktkapitalisierung
$801.50K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-34.44%
Land
US
Handel ZyVersa Therapeutics, Inc. (ZVSA)

Kategorie

Dividendenrendite-Verlauf für ZyVersa Therapeutics, Inc. (ZVSA)
Dividendenrendite (TTM) von ZyVersa Therapeutics, Inc. (Aktienkürzel: ZVSA) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für ZyVersa Therapeutics, Inc. (ZVSA) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber